Genenta Science S.p.A. stock surged after ANEMOCYTE partnership. Discover temferon's cancer trial updates and what’s next.

The partnership leverages Genenta's robust and well-tested LVV Plasmid DNA technology, a platform developed from the foundational research of Professor Luigi Naldini, co-founder of Genenta. This ...

A scaleable method for the liquid-phase separation of plasmid DNA from RNA. In the course of experiments on the potential of nucleic acid compaction for enhancement of chromatographic adsorption ...

Genenta Science (GNTA) and Anemocyte announced a strategic collaboration with a focus on off-the-shelf lentiviral vector Plasmid DNA technology ...

Genenta Science shares surged by more than double Friday after the company said it has partnered with Anemocyte to collaborate on its plasmid DNA technology platform. The stock was briefly halted from ...

Brian Winters is a video game fan from Ocean Springs, Mississippi. He goes to The University of Southern Mississippi and works for the school paper. His favorite video game series are 'Half-Life', ...

IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per planLAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- ...

Investing.com -- 4basebio PLC (AIM:4BB) stock surged 6.9% on Monday after announcing that a global Tier 1 pharmaceutical partner has begun dosing patients in Phase I/II clinical trials using the ...

Plasmid DNA isolation from bacteria is a vital molecular biology method used to create template DNA for preferred downstream reactions. Plasmid isolation approaches are basic; however, high-throughput ...

Plasmidsaurus, the leading global Sequencing as a Service company, today announced the launch of its new RNA-Seq service.